Citadel Advisors
DMK

Citadel Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Citadel Advisors’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60
Closed -$487 – 15529
2023
Q1 		$487 Sell
60
-30
-33% -$398 ﹤0.01% 14486
2022
Q4 		$1.07K Buy
+90
New +$1.03K ﹤0.01% 14530
2022
Q3 		– Sell
-160
Closed -$6K – 13909
2022
Q2 		$6K Buy
160
+9
+6% +$281 ﹤0.01% 12673
2022
Q1 		$6K Sell
151
-96
-39% -$4.12K ﹤0.01% 13417
2021
Q4 		$10K Sell
247
-484
-66% -$30.2K ﹤0.01% 13670
2021
Q3 		$50K Sell
731
-39
-5% -$2.85K ﹤0.01% 13372
2021
Q2 		$59K Sell
770
-304
-28% -$18.5K ﹤0.01% 13267
2021
Q1 		$71K Buy
+1,074
New +$83.6K ﹤0.01% 12727
2019
Q3 		– Sell
-250
Closed -$23K – 9907
2019
Q2 		$23K Sell
250
-300
-55% -$36.5K ﹤0.01% 8930
2019
Q1 		$81K Buy
550
+197
+56% +$38.1K ﹤0.01% 8630
2018
Q4 		$56K Sell
353
-141
-29% -$27K ﹤0.01% 8467
2018
Q3 		$121K Buy
+494
New +$117K ﹤0.01% 8491
2018
Q2 		– Sell
-511
Closed -$125K – 9414
2018
Q1 		$125K Buy
511
+21
+4% +$5.51K ﹤0.01% 7632
2017
Q4 		$151K Buy
490
+274
+127% +$90.1K ﹤0.01% 7272
2017
Q3 		$79K Sell
216
-645
-75% -$229K ﹤0.01% 7094
2017
Q2 		$314K Buy
+861
New +$258K ﹤0.01% 5833

Other funds holding DMK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Citadel Advisors's DMK Position: Q2 2023 in Review

Citadel Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 4,674 shares — an estimated $37.9K sold.

Citadel Advisors first reported a position in DMK in Q4 2016 and held it in 17 quarters. The position peaked at $384K in Q4 2017. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

  • Citadel Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 4,674 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $37.9K.
  • Citadel Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2016 and held it in 17 quarters.
  • Citadel Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $384K in Q4 2017.
  • 22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.